JP2010509241A - 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用 - Google Patents

膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用 Download PDF

Info

Publication number
JP2010509241A
JP2010509241A JP2009535502A JP2009535502A JP2010509241A JP 2010509241 A JP2010509241 A JP 2010509241A JP 2009535502 A JP2009535502 A JP 2009535502A JP 2009535502 A JP2009535502 A JP 2009535502A JP 2010509241 A JP2010509241 A JP 2010509241A
Authority
JP
Japan
Prior art keywords
nanoparticles
peptide
seq
hydrophobic substance
integral membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009535502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509241A5 (https=
Inventor
アイ． タラソヴァ、ナディア
ジー． タラソフ、セルゲイ
ジェイ． ミチェイダ、クリストファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2010509241A publication Critical patent/JP2010509241A/ja
Publication of JP2010509241A5 publication Critical patent/JP2010509241A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009535502A 2006-11-07 2007-11-06 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用 Withdrawn JP2010509241A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86466506P 2006-11-07 2006-11-07
PCT/US2007/083772 WO2008058125A2 (en) 2006-11-07 2007-11-06 Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs

Publications (2)

Publication Number Publication Date
JP2010509241A true JP2010509241A (ja) 2010-03-25
JP2010509241A5 JP2010509241A5 (https=) 2010-12-09

Family

ID=39365311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009535502A Withdrawn JP2010509241A (ja) 2006-11-07 2007-11-06 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用

Country Status (9)

Country Link
US (1) US9326950B2 (https=)
EP (1) EP2086521A2 (https=)
JP (1) JP2010509241A (https=)
CN (1) CN101610759A (https=)
AU (1) AU2007316416A1 (https=)
CA (1) CA2668638A1 (https=)
NZ (1) NZ576769A (https=)
WO (1) WO2008058125A2 (https=)
ZA (1) ZA200903125B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2086521A2 (en) * 2006-11-07 2009-08-12 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs
WO2012162628A2 (en) 2011-05-25 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of ras oncoproteins
EP2911701A4 (en) 2012-10-23 2016-06-08 Univ Johns Hopkins Novel self-assembling drug amphiphiles and methods for synthesis and application
ES2625024B1 (es) * 2015-12-18 2018-05-10 Consejo Superior De Investigaciones Cientificas Material que comprende tectómeros de oligoglicina y nanohilos
US11246924B2 (en) 2016-04-01 2022-02-15 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
WO2019018572A1 (en) * 2017-07-18 2019-01-24 Duke University COMPOSITIONS AND METHODS COMPRISING SELF-ASSEMBLY PEPTIDE-POLYMER NANOFIBERS FOR SUBLINGUAL IMMUNIZATION
WO2026018050A1 (en) 2024-07-14 2026-01-22 Zare Zardini Hadi Pistacia-derived bioactive peptides encapsulated in soy protein nanoparticles as an anticancer drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4121151B2 (ja) * 1996-04-12 2008-07-23 アメリカ合衆国 抗新生物薬および抗レトロウイルス薬として有用なアクリドンから誘導された化合物
AU760208B2 (en) * 1998-02-27 2003-05-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The G protein-coupled receptor antagonists
US7105488B1 (en) * 1998-02-27 2006-09-12 The United States Of America As Represented By The Department Of Health And Human Services G protein-coupled receptor antagonists
US7517849B1 (en) * 1999-11-18 2009-04-14 The United States Of America As Represented By The Secretary Of Health And Human Services Inhibition of ABC transporters by transmembrane domain analogs
DE60100855T2 (de) * 2000-03-07 2004-07-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services 1,8-naphthalimid imidazo[4,5,1-de]acridone mit antitumorwirkung
CN1254234C (zh) 2000-06-09 2006-05-03 莱古伦公司 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
WO2002062823A2 (en) * 2001-02-02 2002-08-15 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2006010083A2 (en) * 2004-07-08 2006-01-26 Molecular Therapeutics, Inc. Biodegradable nanoparticles
EP2086521A2 (en) * 2006-11-07 2009-08-12 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Self-assembling nanoparticles composed of transmembrane peptides and their application for specific intra-tumor delivery of anti-cancer drugs

Also Published As

Publication number Publication date
AU2007316416A1 (en) 2008-05-15
ZA200903125B (en) 2010-05-26
US9326950B2 (en) 2016-05-03
CA2668638A1 (en) 2008-05-15
NZ576769A (en) 2012-01-12
WO2008058125A2 (en) 2008-05-15
WO2008058125A3 (en) 2008-10-16
EP2086521A2 (en) 2009-08-12
US20100034896A1 (en) 2010-02-11
CN101610759A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
Abdellatif et al. Approved and marketed nanoparticles for disease targeting and applications in COVID-19
AU2021200135B2 (en) Liposome compositions and methods of use thereof
Wang et al. Self-assembling peptide-based nanodrug delivery systems
Saad et al. Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
Li et al. Development of a reactive oxygen species (ROS)-responsive nanoplatform for targeted oral cancer therapy
CN111328346A (zh) 基于人铁蛋白和蛋白酶可切割肽的融合蛋白及其作为化学治疗载体的用途
CN102245636A (zh) 用于药物递送的依托泊苷和多柔比星结合物
US20140294967A1 (en) Stable nanocomposition comprising paclitaxel, process for the preparation thereof, its use and pharmaceutical compositions containing it
JP2010509241A (ja) 膜貫通ペプチドからなる自己凝集性ナノ粒子および抗癌剤の特異的腫瘍内送達のためのその利用
WO2017059786A1 (zh) 一种肿瘤靶向的新型多肽
CN110114367B (zh) Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
EP3405429B1 (en) Formation of functionalized nanoparticles by supramolecular co-assembly
CN106924731A (zh) 一种基于光动力疗法和化学疗法的联合肿瘤靶向治疗系统
EP3493852A1 (en) Targeted nanodroplet emulsions for treating cancer
JP7133225B2 (ja) 治療用多標的コンストラクトおよびその使用
WO2024041535A1 (zh) 纳米组合物及其制备方法和用途
US20190290726A1 (en) Protein polymer fusions for subcutaneous delivery of small molecules
CN113244175B (zh) 一种免疫囊泡美登素偶联物及其制备方法与应用
EP3844297A2 (en) Peptides having immunomodulatory properties
CN118373920A (zh) 具有pd-l1靶向性和细胞穿透性的融合肽及其与紫杉醇的偶联物以及制备方法与应用
Yang et al. Silybin Meglumine-Stabilized Nanosuspension Enhances the Therapeutic Efficacy of Silybin Against Hepatic Fibrosis
WO2018183232A2 (en) Peptides and methods for targeted delivery to tumors
Radhika et al. Blood-brain barrier–its implication in drug transport: Novel strategies in drug delivery to the brain
Wu et al. 150 POSTER Effects of dasatinib on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in healthy subjects
Gabathuler et al. 147 POSTER A new Taxol delivery system for the treatment of brain primary or metastatic tumors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101022

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20121105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121105